Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Oxitefonium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 13/20 | 0.76 |
| ▸ | CHRM3 known ✓ | P20309 | 13/20 | 0.76 |
| ▸ | CHRM2 known ✓ | P08172 | 12/20 | 0.76 |
| ▸ | CHRM4 known ✓ | P08173 | 4/20 | 0.76 |
| ▸ | CHRM5 known ✓ | P08912 | 2/20 | 0.44 |
| ▸ | SCN1A | P35498 | 2/20 | 0.56 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.56 |
| ▸ | SCN3A | Q9NY46 | 2/20 | 0.56 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxitefonium SCHEMBL29388802 | 0.99 | CHRM1 (0.73) | CHRM1CHRM3CHRM2CHRM4SCN1A | |
| Methylbenactyzium SCHEMBL60901 | 0.87 | CHRM1 (1.00) | CHRM1CHRM3CHRM2CHRM4SCN1A | |
| Methylbenactyzium SCHEMBL669744 | 0.85 | CHRM1 (0.97) | CHRM1CHRM3CHRM2CHRM4SCN1A | |
| Methylbenactyzium SCHEMBL8446490 | 0.84 | CHRM1 (0.95) | CHRM1CHRM3CHRM2CHRM4SCN1A | |
| Methylbenactyzium SCHEMBL8816404 | 0.84 | CHRM1 (0.94) | CHRM1CHRM3CHRM2CHRM4SCN1A | |
| SCHEMBL5399482 | 0.81 | CHRM3 (0.51) | CHRM1CHRM3CHRM2CHRM4MEN1 | |
| Penthienate SCHEMBL250881 | 0.77 | CHRM1 (0.67) | CHRM1CHRM3CHRM2CHRM4SCN1A | |
| Penthienate SCHEMBL31393386 | 0.76 | CHRM1 (0.68) | CHRM1CHRM3CHRM2CHRM4SCN1A | |
| SCHEMBL28905886 | 0.75 | CHRM3 (0.54) | CHRM1CHRM3CHRM2MEN1POLB | |
| SCHEMBL16053656 | 0.75 | CHRM3 (0.47) | CHRM1CHRM3CHRM2CHRM4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER LTD. (CH) | 2014-06-19 | — | — | US | claimed |
| EP-2691367-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | Hovione Inter Ltd. (CH) | 2014-02-05 | — | — | EP | claimed |
| WO-2012131286-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER. LTD (CH) | 2012-10-04 | — | — | WO | claimed |
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER LTD. (CH) | 2014-06-19 | — | — | US | disclosed |
| EP-2691367-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | Hovione Inter Ltd. (CH) | 2014-02-05 | — | — | EP | disclosed |
| US-8454582-B2 | Methods and devices for the treatment of ocular conditions | SURMODICS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| WO-2012131286-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | HOVIONE INTER. LTD (CH) | 2012-10-04 | — | — | WO | disclosed |
| US-20110159073-A1 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | DEJUAN EUGENE | 2011-06-30 | — | — | US | disclosed |
| US-20080020048-A1 | Treatment of Respiratory Disease | SOSEI R&D LTD (GB) | 2008-01-24 | — | — | US | disclosed |
| US-20070243260-A1 | Treatment of Childhood Asthma | SOSEI R&D LTD (GB) | 2007-10-18 | — | — | US | disclosed |
| EP-1750807-A2 | GLYCOPYRROLATE FOR TREATING CHILDHOOD ASTHMA | Sosei R&D Ltd. (GB) | 2007-02-14 | — | — | EP | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| US-6136984-A | Solid phase and combinatorial synthesis of substituted thiophenes and of arrays of substituted thiophenes | NOVO NORDISK A/S (DK) | 2000-10-24 | — | — | US | disclosed |
| EP-1021435-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED THIOPHENES AND OF ARRAYS OF SUBSTITUTED THIOPHENES | NOVO NORDISK A/S (DK) | 2000-07-26 | — | — | EP | disclosed |
| WO-1998037078-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED THIOPHENES AND OF ARRAYS OF SUBSTITUTED THIOPHENES | NOVO NORDISK A/S (DK) | 1998-08-27 | — | — | WO | disclosed |
| WO-1997040034-A1 | SOLID PHASE AND COMBINATORIAL SYNTHESIS OF SUBSTITUTED THIOPHENES AND OF ARRAYS OF SUBSTITUTED THIOPHENES | NOVO NORDISK A/S (DK) | 1997-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070243260-A1 | Treatment of Childhood Asthma | TSLP, GALR3, PGGT1B | CHRM1 374/4885CHRM3 14/4885CHRM2 218/4885 |
| US-20080020048-A1 | Treatment of Respiratory Disease | GYPA, MRGPRX2, GALR3 | CHRM1 166/4885CHRM3 12/4885CHRM2 94/4885 |
| US-20140171645-A1 | ELECTROPHILIC ALKYLATING REAGENTS, THEIR PREPARATION AND USE | MGMT, MCL1, TOP2B | CHRM1 3157/4885CHRM3 3125/4885CHRM2 2607/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CHRM1 4583/4885CHRM3 4193/4885CHRM2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.